ストックスクリーナーアプリを入手
2.48
0.00%
0.00
アフターアワーズ：
2.48
前日終値:
$2.48
開ける：
$2.48
24時間の取引高:
89,495
Relative Volume:
0.25
時価総額：
$147.80M
収益：
-
当期純損益:
$-52.37M
株価収益率:
-2.1754
EPS:
-1.14
ネットキャッシュフロー:
$-43.09M
1週間 パフォーマンス:
+4.64%
1か月 パフォーマンス:
-9.49%
6か月 パフォーマンス:
-38.77%
1年 パフォーマンス:
-40.24%
1日の値動き範囲:
$2.43
$2.55
1週間の範囲:
$2.33
$2.55
52週間の値動き範囲:
$1.8101
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
925-368-8508
住所
427 PARK ST., CHARLOTTESVILLE
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Marketscreener.com
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - EIN News
Comprehensive Analysis of Growth Drivers and Challenges in the Neurological Biomarkers Market In New Report - WhaTech
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Australia
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com South Africa
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com India
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Canada
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease - The Manila Times
Acumen extends collaboration with Lonza - TipRanks
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for - EIN News
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MSN
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - StockTitan
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MyChesCo
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - StockTitan
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Yahoo Finance
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Drop in Short Interest - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - Quantisnow
Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 9.9% - MarketBeat
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Perhaps timely catching Acumen Pharmaceuticals Inc (ABOS) would be a good idea - SETE News
Acumen Pharmaceuticals Inc (ABOS) stock: A year of ups and downs - US Post News
ABOS’s Market Whiplash: -28.65% YTD Decline, -15.17% Plunge in 30 Days - The InvestChronicle
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - Inkl
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Eledon Pharmaceuticals Inc (ELDN-Q) QuotePress Release - The Globe and Mail
Vanguard Group Inc. Sells 174,494 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
HC Wainwright Comments on Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Grows By 12.7% - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives “Buy” Rating from HC Wainwright - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $6.00 - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com Australia
Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Earnings Results, Misses Expectations By $0.06 EPS - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com India
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com UK
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives Buy Rating from HC Wainwright - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com Australia
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com India
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com UK
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 - InvestorPlace
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials - TipRanks
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights - StockTitan
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):